Provided by Tiger Fintech (Singapore) Pte. Ltd.

Avidity Biosciences, Inc.

28.10
-1.6700-5.61%
Pre-market: 28.00-0.1000-0.36%08:00 EDT
Volume:2.26M
Turnover:63.53M
Market Cap:3.38B
PE:-9.73
High:28.71
Open:28.10
Low:27.43
Close:29.77
Loading ...

Avidity Biosciences (RNA) Soars 11.3%: Is Further Upside Left in the Stock?

Zacks
·
Yesterday

Avidity Biosciences’ Promising Progress in FORTITUDE Study Boosts Buy Rating

TIPRANKS
·
Yesterday

Biotech stocks slide as Marks resignation seen being negative for sector

TipRanks
·
01 Apr

Avidity Biosciences to Participate in Upcoming Investor Conference

PR Newswire
·
01 Apr

Avidity Completes Enrollment in Del-brax Trial's Biomarker Group for Facioscapulohumeral Muscular Dystrophy

MT Newswires Live
·
31 Mar

Avidity Biosciences Inc: Regulatory Alignment on Global Phase 3 Del-Brax Trial Design and Study Initiation Anticipated in Q2 2025

THOMSON REUTERS
·
31 Mar

Avidity Biosciences Inc: Plan to Present Topline Data From Fortitude Dose Escalation Cohorts in Q2 2025

THOMSON REUTERS
·
31 Mar

Avidity Biosciences Completes Enrollment in Biomarker Cohort in Phase 1/2 Fortitude™ Trial for Delpacibart Braxlosiran (Del-Brax) in People Living With Facioscapulohumeral Muscular Dystrophy

THOMSON REUTERS
·
31 Mar

Promising Genomics & Synthetic Biology Stocks to Consider in 2025

Zacks
·
28 Mar

Circio Advances RNA Platform and Strengthens Financial Position

TIPRANKS
·
26 Mar

Avidity Biosciences announces inducement grants under Nasdaq listing rule 5635(C)(4)

Reuters
·
22 Mar

Avidity Biosciences’ Promising Developments in DMD Treatment and Strategic Preparations for Future Success

TIPRANKS
·
19 Mar

Buy Rating for Avidity Biosciences Driven by Strategic Leadership and Patient-Centric Approach

TIPRANKS
·
19 Mar

Avidity Biosciences Price Target Maintained With a $72.00/Share by HC Wainwright & Co.

Dow Jones
·
19 Mar

Press Release: Korro Reports Full Year 2024 Financial Results and Provides Business Updates

Dow Jones
·
18 Mar

Optimistic Buy Rating for Avidity Biosciences Driven by Promising DMD Treatment and Strategic Expansion Plans

TIPRANKS
·
18 Mar

Promising Trial Results and Strong Growth Potential Lead to Buy Rating for Avidity Biosciences

TIPRANKS
·
18 Mar

Avidity Biosciences Is Maintained at Buy by Chardan Capital

Dow Jones
·
17 Mar

Sector Update: Health Care Stocks Decline Premarket Monday

MT Newswires Live
·
17 Mar

Avidity Biosciences Reports Positive Topline Data From Phase 1/2 Trial of Del-Zota to Treat DMD

MT Newswires Live
·
17 Mar